Zobrazeno 1 - 6
of 6
pro vyhledávání: '"AB Morillo Mora"'
Publikováno v:
Late breaking abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5dc35b211d229fe71b824c1bf6bb4f31
https://doi.org/10.1136/ejhpharm-2023-eahp.458
https://doi.org/10.1136/ejhpharm-2023-eahp.458
Publikováno v:
Late breaking abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d71ec585aa20b6ce6a420602baca8497
https://doi.org/10.1136/ejhpharm-2023-eahp.402
https://doi.org/10.1136/ejhpharm-2023-eahp.402
Autor:
V González Rosa, AB Morillo Mora
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance Anticholinergic drugs (ACD) are closely related to serious negative health outcomes in the elderly but they are widely used in these patients. There are several scales in the literature to predict the risk of suffering antic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1af2dfd94e851966e91632b219dd63ed
https://doi.org/10.1136/ejhpharm-2021-eahpconf.341
https://doi.org/10.1136/ejhpharm-2021-eahpconf.341
Autor:
V González Rosa, AB Morillo Mora, MZaragoza Rascon, MI Sierra Torres, E Atienza Gil, M Pajares Alonso
Publikováno v:
Eur J Hosp Pharm
Background Liraglutide is a human glucagon-like peptide-1 analogue (GLP-1) indicated in the treatment of adults with type-2 diabetes mellitus to achieve glycaemic control, combined with oral antidiabetic agents, increases insulin secretion and decrea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edb2131d173e8e0f36259bfdb403c53a
https://doi.org/10.1136/ejhpharm-2018-eahpconf.358
https://doi.org/10.1136/ejhpharm-2018-eahpconf.358
Autor:
MZaragoza Rascon, E Atienza Gil, M Pajares Alonso, V González Rosa, MI Sierra Torres, AB Morillo Mora
Publikováno v:
Eur J Hosp Pharm
BACKGROUND: Antivenom immunoglobulin is a medication made up of antibodies used to treat snake bites. PURPOSE: To describe the effectiveness and safety of snake antivenom in viper bites. MATERIAL AND METHODS: A 44-year-old male patient affected by a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7c7d51794b95d6f4bf6a7f428f51734
https://doi.org/10.1136/ejhpharm-2018-eahpconf.405
https://doi.org/10.1136/ejhpharm-2018-eahpconf.405
Publikováno v:
Eur J Hosp Pharm
Background The high price of biological drugs has become progressively unsustainable to the national health system. The development of biosimilar drugs might represent an option in reducing healthcare costs. Purpose To analyse the economic impact of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06246ac82df05a82f7ef7154a53b57a
https://doi.org/10.1136/ejhpharm-2018-eahpconf.8
https://doi.org/10.1136/ejhpharm-2018-eahpconf.8